FIELD: biochemistry.
SUBSTANCE: invention relates to an antibody or its antigen-binding fragment specifically binding human programmed cell death protein 1 (PD-1). Also disclosed is a pharmaceutical composition comprising said antibody, an immunoconjugate and a fusion protein containing said antibody, an isolated nucleic acid molecule coding said antibody, a recombinant expression vector containing said nucleic acid, a host cell containing said vector. Disclosed is a method of treating a subject using the disclosed antibody.
EFFECT: invention has the ability to effectively treat diseases associated with PD-1 protein expression.
18 cl, 1 dwg, 9 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES TO DOGS' PD-1 | 2014 |
|
RU2732604C2 |
| ANTI-PD-1 ANTIBODIES | 2019 |
|
RU2788095C2 |
| PROGRAMMED CELL DEATH (PD-1) PROTEIN-1 ANTIBODIES AND USE THEREOF | 2017 |
|
RU2725950C1 |
| ANTIBODY TO PD-1, ITS ANTIGEN-BINDING FRAGMENT AND ITS PHARMACEUTICAL USE | 2020 |
|
RU2807484C2 |
| STABLE COMPOSITIONS OF ANTI-TIGIT ANTIBODIES, INDIVIDUALLY AND IN COMBINATION WITH ANTIBODIES AGAINST PROGRAMMED DEATH RECEPTOR 1 (PD-1), AND METHODS OF THEIR USE | 2018 |
|
RU2820576C2 |
| ANTIBODIES AGAINST LIGAND-1 PROGRAMMED DEATH (PD-L1) AND APPLICATION THEREOF | 2017 |
|
RU2721582C1 |
| COMBINATION THERAPY BASED ON T-CELL-ACTIVATING BISPECIFIC ANTIGEN-BINDING MOLECULES AGAINST CD3 AND FOLATE RECEPTOR 1 (FOLR1) AND ANTAGONISTS BINDING TO PD-1 AXIS | 2015 |
|
RU2753902C2 |
| COMBINED FORMULATIONS OF ANTI-LAG3 ANTIBODY AND ANTI-PD-1 ANTIBODY | 2019 |
|
RU2822192C2 |
| IMMUNOTHERAPY USING ANTIBODIES BINDING PROGRAMMED CELL DEATH PROTEIN LIGAND 1 (PD-L1) | 2017 |
|
RU2766582C2 |
| ANTIBODIES TO PD-1 | 2015 |
|
RU2715628C2 |
